Revance Reports Second Quarter 2019 Financial Results, Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Revance Therapeutics (RVNC) Reports Q2 Loss of $0.86/Share
August 5, 2019 4:35 PM EDTRevance Therapeutics (NASDAQ: RVNC) reported Q2 EPS of ($0.86), versus ($0.94) reported last year. Revenue for the quarter came in at $0 , versus $686 thousand reported last year.
2019 Financial Outlook
Revance reiterates its financial guidance provided in February 2019. Revance expects 2019 GAAP operating expense to be in the... More